Search results for "ALZHEIMER'S DISEASE"

showing 10 items of 301 documents

Tumor necrosis-factor-alpha -308 A/G polymorphism is associated with age at onset of Alzheimer's disease.

2006

Abstract Pro-inflammatory cytokines and acute-phase proteins play an important role in Alzheimer's disease (AD) neurodegeneration, and common polymorphisms of genes controlling their production have been shown to be associated with AD. Tumor necrosis factor (TNF)-α is an inflammatory cytokine involved in the local immune response occurring in the central nervous system of AD patients. Genetic variation could contribute to the risk of developing AD or influence the age at the onset of the disease. We genotyped 222 patients (152 women, 70 men; age range 60–87) and 240 non-demented age-matched healthy controls for TNF-α −308 G/A single nucleotide polymorphism (SNP). No significant differences …

MaleApolipoprotein EAgingGenotypemedicine.medical_treatmentSNPSingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideWhite PeopleAlzheimer DiseaseRisk FactorsGenotypecytokinemedicineHumansGenetic Predisposition to DiseaseAge of OnsetAlleleAgedAged 80 and overTumor Necrosis Factor-alphaalzheimer TNF polymorphisms age of onsetMiddle AgedAlzheimer's diseasemedicine.diseaseCytokineItalyinflammationImmunologyFemaleTumor necrosis factor alphaMED/09 - MEDICINA INTERNAAge of onsetAlzheimer's diseaseTNF-alphaDevelopmental Biology
researchProduct

Lack of association between angiotensin converting enzyme polymorphism and sporadic Alzheimer's disease

2002

Epidemiological and pathogenetic evidences suggest a strong association between vascular risk factors and sporadic Alzheimer's disease (sAD). In agreement with the vascular hypothesis of AD, the role of various candidate genes for atherosclerosis has been investigated, leading to conflicting results. In order to clarify the significance of angiotensin-converting enzyme (ACE) gene insertion (I)/deletion (D) polymorphism in a group of patients with sAD, we conducted a case-control study including 149 cases and 149 age and sex matched controls. All subjects were genotyped for ACE and Apolipoprotein E (APOE). There were no significant differences in ACE genotype or allele frequencies between ca…

MaleApolipoprotein ECandidate genemedicine.medical_specialtySettore MED/09 - Medicina InternaGenotypeDiseasePeptidyl-Dipeptidase ABiologyApolipoproteins EGene FrequencyAlzheimer DiseaseRisk FactorsInternal medicineGenetic predispositionmedicineHumansPolymorphismAllele frequencyAgedAged 80 and overPolymorphism GeneticNeuroscience (all)General NeuroscienceCase-control studyCase-control studyAngiotensin-converting enzymeMiddle AgedAlzheimer's diseasemedicine.diseaseEndocrinologyCase-Control Studiesbiology.proteinFemaleSettore MED/26 - NeurologiaApolipoprotein EAlzheimer's diseaseAngiotensin-converting enzymeNeuroscience Letters
researchProduct

Association between apolipoprotein E epsilon4 allele and apathy in probable Alzheimer's disease.

2006

OBJECTIVE: There have been inconclusive results to date on the association between the Apolipoprotein E (ApoE) genotype and neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD). We investigated whether ApoE epsilon4 allele is associated with NPS in probable AD. METHOD: Data for 197 subjects with probable AD were analysed. The Neuropsychiatric Inventory was used to evaluate the frequency and severity of NPS. Multiple logistic regression models were used to test the association between ApoE genotype and NPS in AD. RESULTS: The ApoE epsilon3/3 genotype was present in 52.3%, epsilon3/4 in 44.1%, and epsilon4/4 in 3.6% of patients. ApoE epsilon4 carriers showed a higher frequency of apath…

MaleApolipoprotein EGenotypeApolipoprotein E4DiseaseNeuropsychological TestsSeverity of Illness IndexApolipoproteins EDegenerative diseaseAlzheimer Diseasemental disordersGenotypemedicineHumansDementiaApathyAllelebehavioural symptomAllelesAgedapolipoprotein EMood DisordersAlzheimer's diseasemedicine.diseasePsychiatry and Mental healthImmunologyFemalelipids (amino acids peptides and proteins)Settore MED/26 - NeurologiaAlzheimer's diseasemedicine.symptomPsychologyNeurosciencelogistic modelsdementia
researchProduct

Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease

2013

Eleven susceptibility loci for late-onset Alzheimer's disease (LOAD) were identified by previous studies; however, a large portion of the genetic risk for this disease remains unexplained. We conducted a large, two-stage meta-analysis of genome-wide association studies (GWAS) in individuals of European ancestry. In stage 1, we used genotyped and imputed data (7,055,881 SNPs) to perform meta-analysis on 4 previously published GWAS data sets consisting of 17,008 Alzheimer's disease cases and 37,154 controls. In stage 2, 11,632 SNPs were genotyped and tested for association in an independent set of 8,572 Alzheimer's disease cases and 11,312 controls. In addition to the APOE locu…

MaleApolipoprotein Eepidemiology [Alzheimer Disease]SORL1Medizingenetics [Alzheimer Disease]Genome-wide association studySingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideArticlePICALMCohort StudiesAlzheimer Diseaseddc:570PSEN2GeneticsmedicineHumansGenetic Predisposition to DiseaseAge of OnsetBiologyAgedGenetic associationAged 80 and overGeneticsMiddle Agedmedicine.diseaseGenetic LociCase-Control StudiesFemaleHuman medicineAlzheimer's diseasestatistics & numerical data [Genome-Wide Association Study]Genome-Wide Association StudyNature Genetics
researchProduct

Apoe genotypes and brain imaging classes in normal cognition, mild cognitive impairment, and alzheimer’s disease: A longitudinal study

2020

Objective: To evaluate in 419 stroke-free cognitively normal subjects (CN) aged 45-82 years covering during a long prospective study (11.54 ± 1.47 years) the preclinical to dementia spectrum: 1) the distribution of small vessel disease (V) and brain atrophy (A) aggregated as following: V−/A−, V−/A+, V+/A−, V+/A+; 2) the relationship of these imaging classes with individual apolipoprotein E (APOE) genotypes; 3) the risk of progression to Alzheimer Disease (AD) of the individual APOE genotypes. Methods: Participants underwent one baseline (t0), and 4 clinical and neuropsychological assessments (t1,t2,t3, and t4). Brain MRI was performed in all subjects at t0, t2, t3 and t4.. White matter hyp…

MaleApolipoprotein Emedicine.medical_specialtyGenotypeApolipoprotein E4NeuroimagingNeuropsychological TestsAPOE genotypes Brain imaging classes Caudate atrophy Global cerebral atrophy Lacunes White matter hyperintensities Aged Aged 80 and over Alzheimer Disease Apolipoprotein E4 Apolipoproteins E Brain Case-Control Studies Cognitive Dysfunction Disease Progression Female Genotype Humans Longitudinal Studies Magnetic Resonance Imaging Male Middle Aged Neuroimaging Neuropsychological Tests Risk Factorsbrain imaging classesApolipoproteins EAtrophyNeuroimagingAlzheimer DiseaseRisk FactorsInternal medicineGlobal brain atrophymedicineHumansDementiaCognitive DysfunctionLongitudinal Studiescaudate atrophyAgedglobal cerebral atrophyAged 80 and overAPOE genotypesbusiness.industryNeuropsychologyBrainMiddle Agedwhite matter hyperintensitiesmedicine.diseaseMagnetic Resonance ImagingHyperintensityNeurologyCase-Control StudiesDisease ProgressionCardiologyFemaleNeurology (clinical)Alzheimer's diseasebusiness
researchProduct

Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions

1999

In recent research, apolipoprotein-E (apoE) polymorphism has been shown to influence the formation of neurofibrillary changes and the accumulation of beta/A4-amyloid, the histopathological hallmarks of Alzheimer's disease (AD). Clinical studies associate the apoE allele epsilon4 with earlier onset of the disease, although the clinical speed of progression remains unchanged. Time course estimates have also provided evidence which indicates that the clinical phase of AD constitutes only 10-20% of the total time span needed for the development of this slowly progressing degenerative brain disorder. Due to the lack of reliable clinical tests for the detection of pre-symptomatic stages of AD, we…

MaleApolipoprotein Emedicine.medical_specialtyPathologyGenotypeApolipoprotein BApolipoprotein E2Apolipoprotein E4Apolipoprotein E3tau ProteinsNeuropathologyPathology and Forensic MedicineCellular and Molecular NeuroscienceApolipoproteins EDegenerative diseaseIsomerismAlzheimer DiseaseInternal medicineGenotypemedicineHumansAlleleAllelesBrain ChemistryAmyloid beta-PeptidesPolymorphism GeneticbiologyBrainNeurofibrillary TanglesNeurofibrillary tangleMiddle Agedmedicine.diseaseEndocrinologyDisease Progressionbiology.proteinFemaleNeurology (clinical)Alzheimer's diseaseActa Neuropathologica
researchProduct

Beta-adrenoceptor density and subtype distribution in cerebellum and hippocampus from patients with Alzheimer's disease

1993

beta-Adrenoceptor density and beta 1- and beta 2-subtype distribution were examined in hippocampi and cerebella from patients with Alzheimer's disease (AD/SDAT). Tissues from age-, sex and post-mortem delay matched non-demented patients served as controls. The total beta-adrenoceptor density as evaluated in saturation experiments with the hydrophilic radioligand [3H]CGP 12177 was higher in hippocampal (36-39 fmol/mg protein) than cerebellar tissues (20-21 fmol/mg), however, no differences were found in either brain region between AD/SDAT patients and controls. Subtype distribution using the highly selective beta 1-adrenoceptor antagonist CGP 20712A revealed a slightly higher proportion of b…

MaleCerebellummedicine.medical_specialtyAdrenergic beta-AntagonistsHippocampal formationTritiumBinding CompetitiveHippocampusPropanolaminesAdenylyl cyclaseBasal (phylogenetics)chemistry.chemical_compoundDegenerative diseaseAlzheimer DiseaseCerebellumInternal medicineReceptors Adrenergic betamedicineHumansHippocampus (mythology)AgedAged 80 and overPharmacologybusiness.industryImidazolesAntagonistGeneral MedicineMiddle Agedmedicine.diseaseKineticsmedicine.anatomical_structureEndocrinologychemistryDementiaFemaleAlzheimer's diseasebusinessNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

The default mode network and the working memory network are not anti-correlated during all phases of a working memory task

2015

INTRODUCTION:\ud \ud The default mode network and the working memory network are known to be anti-correlated during sustained cognitive processing, in a load-dependent manner. We hypothesized that functional connectivity among nodes of the two networks could be dynamically modulated by task phases across time.\ud METHODS:\ud \ud To address the dynamic links between default mode network and the working memory network, we used a delayed visuo-spatial working memory paradigm, which allowed us to separate three different phases of working memory (encoding, maintenance, and retrieval), and analyzed the functional connectivity during each phase within and between the default mode network and the …

MaleCingulate cortexComputer scienceFunctional magnetic resonance imagingCINGULATE CORTEX0302 clinical medicinePrefrontal cortexALZHEIMERSDefault mode networkCerebral CortexDefault mode network; female; Functional magnetic resonance imaging; Working memoryMultidisciplinarymedicine.diagnostic_testArtificial neural networkQ05 social sciencesRCognitionHuman brainFUNCTIONAL CONNECTIVITYFLUCTUATIONSMagnetic Resonance ImagingMemory Short-Termmedicine.anatomical_structurefemaleCerebral cortexConnectomeMedicineSettore MED/26 - NeurologiaAlzheimer's diseasedefault mode network; working memory; functional magnetic resonance imaging; functional connectivity; Brain networksResearch ArticleHumanCognitive psychologyAdultBrain networksScienceRETRIEVALPosterior parietal cortex050105 experimental psychologyYoung Adult03 medical and health sciencesPARIETAL CORTEXTask-positive networkEncoding (memory)ConnectomemedicineHumans0501 psychology and cognitive sciencesMODULATIONBRAIN-FUNCTIONResting state fMRIWorking memoryWorking memorymedicine.diseaseR1COMPONENTDefault mode networkRESTING-STATEFunctional magnetic resonance imaging030217 neurology & neurosurgery
researchProduct

Amygdala-hippocampal atrophy and memory performance in dementia of Alzheimer type.

1997

The aim of the present study was to examine the involvement of brain structures, especially the amygdala-hippocampal complex, in dementia of Alzheimer type (DAT), and to assess the relation of amygdala-hippocampal atrophy with memory dysfunction. 14 patients with DAT and 10 healthy age-matched controls were examined with different neuropsychologic tests including the UCLA-Auditory Verbal Learning Test. MRI was performed with a conventional 1.5-tesla scanner. Atrophy was found in many brain structures of demented subjects in comparison with healthy age-matched controls. The volumes of amygdala-hippocampal complexes and of the temporal lobes of demented subjects were more reduced than the tot…

MaleCognitive NeuroscienceNeuropsychological TestsVerbal learningHippocampusSeverity of Illness IndexTemporal lobeAtrophyAlzheimer DiseasemedicineDementiaHumansMemory disorderAgedMemory DisordersCerebral degenerationMiddle Agedmedicine.diseaseAmygdalaMagnetic Resonance ImagingTemporal LobePsychiatry and Mental healthnervous systemBrain sizeFemaleGeriatrics and GerontologyAlzheimer's diseaseAtrophyPsychologyNeuroscienceDementia and geriatric cognitive disorders
researchProduct

Increased CSF APPs-  levels in patients with Alzheimer disease treated with acitretin

2014

Objective: We investigated induction of α-secretase A disintegrin and metalloprotease 10 (ADAM10) by the synthetic retinoid acitretin (Neotigason; Actavis, Munchen-Riem, Germany) in patients with mild to moderate Alzheimer disease (AD) via measurement of CSF content of α-secretase–derived amyloid precursor protein (APPs-α). Methods: Twenty-one patients clinically diagnosed with mild to moderate AD received acitretin (30 mg per day) or placebo in a 4-week double-blind study. Primary endpoint was the difference of CSF APPs-α ratios calculated from the APPs-α levels after treatment and at baseline. We monitored safety and tolerability of the treatment. In addition, we assessed biomarkers such …

MaleDrugmedicine.medical_specialtymedia_common.quotation_subjectPilot ProjectsPlaceboGastroenterologyAcitretinlaw.inventionDouble-Blind MethodRandomized controlled trialAlzheimer Diseasecerebrospinal fluid [Amyloid Precursor Protein Secretases]lawInternal medicinemedicineClinical endpointdrug therapy [Alzheimer Disease]Humansddc:610Prospective StudiesProspective cohort studyAgedmedia_commonbusiness.industrytherapeutic use [Acitretin]diagnosis [Alzheimer Disease]Middle Agedmedicine.diseaseAcitretincerebrospinal fluid [Alzheimer Disease]Treatment Outcomecerebrospinal fluid [Biomarkers]TolerabilityFemaleNeurology (clinical)Amyloid Precursor Protein SecretasesAlzheimer's diseasebusinessBiomarkersmedicine.drugNeurology
researchProduct